Purchase Order 75F40118P20106

Award Date 6/29/18
Potential Completion Date 7/15/20
Potential Value $215K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Morrisville, NC, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
We Pharma, Inc. doing business as WEP Clinical has been awarded a firm fixed price delivery order valued at $2,000,000 by the Department of Health and Human Services' Food and Drug Administration (HHS FDA) to provide pharmaceutical products and services in support of FDA operations. This task order was issued against We Pharma's existing indefinite delivery contract with HHS FDA, valued at $6 million over five years, to supply drug products and emergency delivery services for FDA research and...
We Pharma, Inc. doing business as WEP Clinical has been awarded a firm fixed price delivery order valued at one hundred thousand dollars from the Department of Health and Human Services' Food and Drug Administration (HHS FDA) to provide currently marketed drug products for FDA research studies. This order was issued against the company's existing five-year, nine and a half million dollar contract awarded in 2020 by HHS FDA to supply drug products for internal research in support of the...
<p>The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $409,719 firm fixed price delivery order contract to We Pharma, Inc., doing business as WEP Clinical, for Pharmaceutical Drug Product Orders. The contract has a period of performance starting on July 31, 2023 through August 6, 2024 and will be performed in Silver Spring, Maryland.</p>
The Department of Health and Human Services Food and Drug Administration awarded a $169,918.01 firm fixed price delivery order contract to We Pharma, Inc. of Morrisville, North Carolina. The purpose of this requirement is to obtain currently marketed drug products for FDA research studies. We Pharma will provide the requested products to the FDA under this contract, which has a completion date of September 29, 2021. No set-aside designation was used for this award made on September 30, 2020.
This delivery order against the Department of Health and Human Services Food and Drug Administration is for the purpose of obtaining currently marketed drug products for FDA research studies. Awarded on September 30, 2020 to We Pharma, Inc. located in Morrisville, North Carolina, this firm fixed price contract has a potential value of $246,754.22 and period of performance through September 29, 2021. No set-aside designation was applied. We Pharma Inc. will provide the requested drug products...
The Department of Health and Human Services Food and Drug Administration awarded a $145,636.17 firm fixed price delivery order to We Pharma, Inc. of Silver Spring, Maryland for pharmaceutical products to support domestic manufacturing. No set-aside provisions were applied to this contract. We Pharma will provide the FDA's Office of Pharmaceutical Quality with domestic pharmaceutical manufacturing supplies through September 30th, 2022 at their Silver Spring location. As the regulatory body...
The Department of Health and Human Services Food and Drug Administration awarded a firm fixed-price purchase order to The Pharma Letter LIMITED, a for-profit organization, for a $113,008.00 pharmaceutical subscription for 25 users. The contract has a performance period ending May 20, 2025, with an award date of May 20, 2020. The subscription provides the FDA's Office of Global Policy and Strategy (OGPS) staff with access to global news, expert commentary, and analysis on pharmaceutical, generic,...
The Department of Health and Human Services Food and Drug Administration awarded a $207,623 purchase order to Clarivate Analytics (Us) LLC for ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURER DATA ACQUISITION. Under this firm fixed price contract, Clarivate Analytics will provide data acquisition services to the FDA relating to API manufacturers. Performance will take place in Silver Spring, Maryland over approximately one year, from September 2023 through September 2024. As the regulator of...
This $227,480 firm fixed price purchase order was awarded by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to Clarivate Analytics (Us) LLC, a global provider of scientific research databases and analytics platforms. The contract is for data acquisition services related to active pharmaceutical ingredient (API) manufacturing, with a completion date of September 24, 2023. Clarivate Analytics, a foreign-owned for-profit company, has held multiple indefinite...
This is a $435,000 firm-fixed-price purchase order awarded by the Food and Drug Administration (FDA), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Pragmatic Data LLC, a small disadvantaged business. The contract is for scientific and technical consulting services to support the FDA's Structured Product Labeling (SPL) data standard, which is used for the electronic submission of product information. Pragmatic Data LLC will provide expertise and...

This firm-fixed-price purchase order was awarded by the Food and Drug Administration (FDA), a civilian agency under the Department of Health and Human Services, to We Pharma, Inc., a self-certified small disadvantaged business. The $214,914.90 contract is for the provision of "PHYSICOCHEMICAL PRODUCTS" and has a total small business set-aside. The award supports the FDA's regulatory science program and provides pharmaceutical drug products for the agency's research, compliance, and emergency response activities. We Pharma, doing business as WEP Clinical, is an established supplier of currently marketed drug products to the FDA, having received multiple contracts ranging from $100,000 to over $2 million. The company also holds two significant Indefinite Delivery Contracts with the FDA, valued at $9.5 million and $6 million, further solidifying its role as a key pharmaceutical provider for the agency.

Generated 6/29/25, 1:27 AM